Connection

Jonathan Douxfils to Humans

This is a "connection" page, showing publications Jonathan Douxfils has written about Humans.
Connection Strength

0.189
  1. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021 Dec; 10(1):1495-1498.
    View in: PubMed
    Score: 0.008
  2. Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ. J Infect. 2021 10; 83(4):e4-e5.
    View in: PubMed
    Score: 0.008
  3. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. Viruses. 2021 07 14; 13(7).
    View in: PubMed
    Score: 0.008
  4. Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination. J Infect. 2022 01; 84(1):94-118.
    View in: PubMed
    Score: 0.008
  5. Evaluations of SARS-CoV-2 Serological Assay Performance Need Inclusion of Long-Term Samples. J Clin Microbiol. 2021 05 19; 59(6).
    View in: PubMed
    Score: 0.008
  6. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021 07; 203:163-171.
    View in: PubMed
    Score: 0.008
  7. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). Clin Microbiol Infect. 2021 Sep; 27(9):1351.e5-1351.e7.
    View in: PubMed
    Score: 0.008
  8. Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients. Clin Chem Lab Med. 2021 04 27; 59(5):e179-e183.
    View in: PubMed
    Score: 0.007
  9. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins. J Med Virol. 2021 04; 93(4):2262-2269.
    View in: PubMed
    Score: 0.007
  10. Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study. Clin Chem Lab Med. 2020 09 25; 58(10):e193-e196.
    View in: PubMed
    Score: 0.007
  11. Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total Antibodies. Clin Chem. 2020 08 01; 66(8):1104-1106.
    View in: PubMed
    Score: 0.007
  12. Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia. Br J Haematol. 2020 08; 190(4):e187-e189.
    View in: PubMed
    Score: 0.007
  13. The role of serology for COVID-19 control: Population, kinetics and test performance do matter. J Infect. 2020 08; 81(2):e91-e92.
    View in: PubMed
    Score: 0.007
  14. Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. J Thromb Haemost. 2019 08; 17(8):1273-1287.
    View in: PubMed
    Score: 0.007
  15. An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol. 2019 May; 41 Suppl 1:33-39.
    View in: PubMed
    Score: 0.007
  16. Optimal wavelength for the clot waveform analysis: Determination of the best resolution with minimal interference of the reagents. Int J Lab Hematol. 2019 Jun; 41(3):316-324.
    View in: PubMed
    Score: 0.006
  17. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. Int J Lab Hematol. 2019 Apr; 41(2):250-261.
    View in: PubMed
    Score: 0.006
  18. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide. Thromb Haemost. 2018 Jul; 118(7):1203-1214.
    View in: PubMed
    Score: 0.006
  19. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018 02; 16(2):209-219.
    View in: PubMed
    Score: 0.006
  20. An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. Thromb Res. 2017 Sep; 157:29-37.
    View in: PubMed
    Score: 0.006
  21. Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thromb Res. 2017 08; 156:36-38.
    View in: PubMed
    Score: 0.006
  22. Laboratory Assessment of Direct Oral Anticoagulants. Semin Thromb Hemost. 2017 Apr; 43(3):277-290.
    View in: PubMed
    Score: 0.006
  23. Measuring Direct Oral Anticoagulants. Methods Mol Biol. 2017; 1646:217-225.
    View in: PubMed
    Score: 0.006
  24. Clinical performance of the Panbio assay for the detection of SARS-CoV-2 IgM and IgG in COVID-19 patients. J Med Virol. 2021 May; 93(5):3277-3281.
    View in: PubMed
    Score: 0.002
  25. An original multiplex method to assess five different SARS-CoV-2 antibodies. Clin Chem Lab Med. 2021 04 27; 59(5):971-978.
    View in: PubMed
    Score: 0.002
  26. Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance, and their limitations. J Thromb Haemost. 2020 11; 18(11):3121-3124.
    View in: PubMed
    Score: 0.002
  27. Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. Thromb Res. 2021 01; 197:20-23.
    View in: PubMed
    Score: 0.002
  28. [Management of the thrombotic risk associated with COVID-19: what is the role of the hemostasis laboratory?] Ann Biol Clin (Paris). 2020 10 01; 78(5):471-481.
    View in: PubMed
    Score: 0.002
  29. High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies. Clin Biochem. 2020 Dec; 86:23-27.
    View in: PubMed
    Score: 0.002
  30. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. Clin Chem Lab Med. 2020 Jul 28; 58(8):1357-1364.
    View in: PubMed
    Score: 0.002
  31. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. J Med Virol. 2021 02; 93(2):803-811.
    View in: PubMed
    Score: 0.002
  32. Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass. J Am Coll Cardiol. 2019 10 29; 74(17):2178-2189.
    View in: PubMed
    Score: 0.002
  33. Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles. Medicine (Baltimore). 2019 Jul; 98(27):e16164.
    View in: PubMed
    Score: 0.002
  34. Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE. Thromb Haemost. 2019 Apr; 119(4):675-684.
    View in: PubMed
    Score: 0.002
  35. The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation. Thromb Res. 2018 11; 171:160-166.
    View in: PubMed
    Score: 0.002
  36. Reduction of the turn-around time for the measurement of rivaroxaban and apixaban: Assessment of the performance of a rapid centrifugation method. Int J Lab Hematol. 2018 12; 40(6):e105-e108.
    View in: PubMed
    Score: 0.002
  37. The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs. Thromb Res. 2018 08; 168:63-66.
    View in: PubMed
    Score: 0.002
  38. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018 03; 118(3):437-450.
    View in: PubMed
    Score: 0.002
  39. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opin Biol Ther. 2017 10; 17(10):1275-1296.
    View in: PubMed
    Score: 0.001
  40. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme. Int J Lab Hematol. 2017 Aug; 39(4):402-408.
    View in: PubMed
    Score: 0.001
  41. Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. Blood Transfus. 2018 02; 16(2):163-172.
    View in: PubMed
    Score: 0.001
  42. Inactivation of human coagulation factor X by a protease of the pathogen Capnocytophaga canimorsus. J Thromb Haemost. 2017 03; 15(3):487-499.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.